Abstract |
Current strategies for hepatic gene therapy are either quantitatively inefficient or suffer from lack of permanent gene expression. We have utilized an animal model of hereditary tyrosinaemia type I (HT1), a recessive liver disease caused by deficiency of fumarylacetoacetate hydrolase (FAH), to determine whether in vivo selection of corrected hepatocytes could improve the efficiency of liver gene transfer. As few as 1,000 transplanted wild-type hepatocytes were able to repopulate mutant liver, demonstrating their strong competitive growth advantage. Mutant hepatocytes corrected in situ by retroviral gene transfer were also positively selected. In mutant animals treated by multiple retrovirus injections >90% of hepatocytes became FAH positive and liver function was restored to normal. Our results demonstrate that in vivo selection is a useful strategy for hepatic gene therapy and may lead to effective treatment of human HT1 by retroviral gene transfer.
|
Authors | K Overturf, M Al-Dhalimy, R Tanguay, M Brantly, C N Ou, M Finegold, M Grompe |
Journal | Nature genetics
(Nat Genet)
Vol. 12
Issue 3
Pg. 266-73
(Mar 1996)
ISSN: 1061-4036 [Print] United States |
PMID | 8589717
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Cyclohexanones
- Enzyme Inhibitors
- Nitrobenzoates
- Tyrosine
- Hydrolases
- fumarylacetoacetase
- nitisinone
|
Topics |
- Amino Acid Metabolism, Inborn Errors
(metabolism, therapy)
- Animals
- Cell Count
- Cell Transplantation
- Cyclohexanones
(pharmacology)
- Disease Models, Animal
- Enzyme Inhibitors
(pharmacology)
- Genetic Therapy
(adverse effects)
- Humans
- Hydrolases
(antagonists & inhibitors, deficiency, genetics)
- Immunoenzyme Techniques
- Liver
(cytology, drug effects, metabolism)
- Liver Function Tests
- Liver Neoplasms
(etiology)
- Male
- Mice
- Mice, Inbred C57BL
- Nitrobenzoates
(pharmacology)
- Retroviridae
(genetics)
- Tyrosine
(blood)
|